Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Jul;69(1):14-8.

Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand

Udomsak Silachamroon  1 , Srivicha Krudsood, Sombat Treeprasertsuk, Polrat Wilairatana, Kobsiri Chalearmrult, Hla Yin Mint, Pannamas Maneekan, Nicholas J White, Victor R Gourdeuk, Gary M Brittenham, Sornchai Looareesuwan
Affiliations
Clinical Trial

Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand

Udomsak Silachamroon et al. Am J Trop Med Hyg. 2003 Jul.

Abstract

We studied prospectively 801 Thai patients admitted to the Bangkok Hospital for Tropical Diseases with acute, symptomatic Plasmodium vivax malaria to determine the optimum duration of treatment with oral artesunate and the safety, tolerability, and effectiveness of a high dose of primaquine in prevention of relapse. Patients were randomly assigned to one of four treatment groups: 1) a five-day course of artesunate (Group A5); 2) a seven-day course of artesunate (Group A7); 3) a five-day course of artesunate plus a 14-day course of high-dose primaquine (0.6 mg/kg, maximum dose = 30 mg) (Group A5 + P); and 4) a seven-day course of artesunate plus a 14-day course of high-dose primaquine (Group A7 + P). During 28 days of observation, P. vivax reappeared in the blood of 50% of those who received artesunate alone (Groups A5 and A7), compared with none of those who received primaquine (Groups A5 + P and A7 + P; P < 0.0001). Adverse effects were confined to the 13 patients with a deficiency for glucose-6-phosphate dehydrogenase; high-dose primaquine (0.6 mg/kg of base a day) had to be stopped in four (31%) patients because of a significant decrease in the hematocrit. The combination of five days of artesunate and 14 days of primaquine is a highly effective and generally well-tolerated treatment regimen for vivax malaria in Thailand.

PubMed Disclaimer

References

    1. Chareonviriyaphap T, Bangs MJ, Ratanatham S. Status of malaria in Thailand. Southeast Asian J Trop Med Public Health. 2000;31:225–237. - PubMed
    1. Luxemburger C, Kyaw Ley Thew, White NJ, Webster HK, Kyle DE, Maelankiri L, Chongsuphajaisiddhi T, Nosten F. The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg. 1996;90:105–111. - PubMed
    1. Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, Sookto P, Wimonwattrawatee T, Looareesuwan S, White NJ, Nosten F. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg. 2000;94:537–544. - PMC - PubMed
    1. Looareesuwan S, Olliaro P, White NJ, Chongsuphajaisiddhi T, Sabcharoen A, Thimasarn K, Nosten F, Singhasivanon P, Supavej S, Khusmith S, Wyling S, Kanyok T, Walsh D, Leggat PA, Doberstyn EB. Consensus recommendation on the treatment of malaria in Southeast Asia. Southeast Asian J Trop Med Public Health. 1998;29:355–360. - PubMed
    1. Tan-ariya P, Na-Bangchang K, Tin T, Limpaibul L, Brockelman CR, Karbwang J. Clinical response and susceptibility in vitro of Plasmodium vivax to the standard regimen of chloroquine in Thailand. Trans R Soc Trop Med Hyg. 1995;89:426–429. - PubMed

Publication types

MeSH terms

LinkOut - more resources